Literature DB >> 8513819

Comparative pharmacokinetics of ciprofloxacin, ofloxacin and pefloxacin in human aqueous humour.

H Giamarellou1, D Kanellas, E Kavouklis, G Petrikkos, L Gabriel.   

Abstract

Eighty-five patients undergoing cataract surgery were given for prophylaxis of intraocular infection two intravenous doses each of 200 mg, 300 mg or 400 mg ciprofloxacin (35 patients), 400 mg or 800 mg pefloxacin (30 patients), or 400 mg ofloxacin (20 patients). Ciprofloxacin levels in aqueous humour ranged from 0.02 to 0.50 microgram/ml, pefloxacin levels from 1.04 to 7.80 micrograms/ml, and ofloxacin levels from 0.44 to 2.27 micrograms/ml with ratios of aqueous humour to serum levels ranging from 3.8% to 25%, 21% to 48.1% and 44% to 88.4%, respectively. It is concluded that the quinolones studied might be suitable for surgical prophylaxis or treatment of anterior chamber infections due to Enterobacteriaceae, while ciprofloxacin at high doses is preferable for Pseudomonas aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513819     DOI: 10.1007/BF01967262

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  [Intraocular penetration of ciprofloxacin after infusion and oral administration].

Authors:  M Mounier; J P Adenis; F Denis
Journal:  Pathol Biol (Paris)       Date:  1988-06

2.  Bacterial resistance to antibiotics in the United States. Ten million strains, nine species and sixteen antibiotics.

Authors:  V Lorian; B Atkinson
Journal:  Drugs Exp Clin Res       Date:  1987

3.  Ofloxacin in human aqueous humour and lens.

Authors:  A Fisch; C Lafaix; A Salvanet; M Cherifi; A Meulemans
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

4.  The quinolones.

Authors:  R J Fass
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

5.  [Diffusion of fluoroquinolones in the aqueous humor and crystalline lens].

Authors:  C Lafaix; A Salvanet; A Fisch; F Forestier; G Montay; A Meulemans
Journal:  Pathol Biol (Paris)       Date:  1987-06

6.  [Intraocular penetration of pefloxacin in man and rabbit. The aqueous humor and vitreous body].

Authors:  F Denis; M Mounier; J P Adenis
Journal:  Pathol Biol (Paris)       Date:  1987-06

7.  Transscleral iontophoresis of gentamicin in monkeys.

Authors:  M Barza; C Peckman; J Baum
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-06       Impact factor: 4.799

8.  Ciprofloxacin concentrations in human aqueous humor following intravenous administration.

Authors:  W Behrens-Baumann; J Martell
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

9.  [Intracameral penetration of pefloxacine in man].

Authors:  A Bron; D Talon; B Delbosc; J M Estavoyer; F Prost; M Montard
Journal:  J Fr Ophtalmol       Date:  1986       Impact factor: 0.818

10.  Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  H Giamarellou; N Galanakis; C Dendrinos; J Stefanou; E Daphnis; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  4 in total

1.  Penetration of gentamicin and ofloxacin in human vitreous after systemic administration.

Authors:  H Verbraeken; A Verstraete; E Van de Velde; G Verschraegen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

Review 2.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 3.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

4.  A UPLC-MS Method for the Determination of Ofloxacin Concentrations in Aqueous Humor.

Authors:  Panagiotis Plotas; Charalampos Anastasopoulos; Olga E Makri; Michalis Leotsinidis; Constantine D Georgakopoulos
Journal:  Anal Chem Insights       Date:  2014-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.